PGR and breast cancer: The molecular subtypes of BC have distinct pathological features and are characterised by amplification of their hormone receptors, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2), or the absence thereof in triple-negative BC (TNBC) (2, 3).